This trial is evaluating whether CD47 Antagonist ALX148 will improve 2 primary outcomes and 6 secondary outcomes in patients with Composite Lymphoma. Measurement will happen over the course of Up to 28 days.
This trial requires 52 total participants across 1 different treatment group
This trial involves a single treatment. CD47 Antagonist ALX148 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"There have been many advances in treating lymphoma patients, but the outcomes remain unsatisfactory. It seems that we cannot expect dramatic breakthroughs for treating lymphoma until we understand the biology of this disease better. Future studies need to focus on identifying specific molecular markers to predict response to treatment and to identify new target molecules for developing novel agents." - Anonymous Online Contributor
"The CD47 antigen has been shown to be overexpressed in B cell lymphomas including mantle-cell lymphoma and Burkitt's lymphoma. Therefore, targeting solely CD47 using monoclonal antibody therapy does not appear to be sufficient for effective treatment. In addition, there is increasing evidence that the CD47 molecule plays a role in modulating BCR signalling and may therefore not be an ideal target in treating these cancers." - Anonymous Online Contributor
"Results from a recent paper shows that CD47 blockade may be safely combined with chemotherapy in patients with low-grade non-Hodgkin's lymphoma and in mantle cell lymphoma without increasing the rate of myelosuppression. The combination of CD47 antagonism with standard chemotherapy allows for a targeted approach to chemotherapy." - Anonymous Online Contributor
"We were not able to demonstrate any significant difference in PFS between patients treated with Alx148 or a placebo. In this exploratory analysis of PFS using an intent to treat analysis, there was no indication of a benefit of Alx148 over a placebo. However, future studies will have to confirm our findings." - Anonymous Online Contributor
"Tumor-related factors such as stage, type of cell, and presence of B-cell markers influence response. Drugs used for other cancers (e.g., anthracyclines, alkylating agents, taxanes) are often used as well as chemotherapy regimens for lymphomas. Complete responders to immunotherapy agents or radiotherapy were also treated with chemotherapy or radiotherapy plus autoimmunotherapy. The majority of patients who responded to therapy went into remission. Most of these patients continued with treatment and showed disease stabilization in about half of them. Treatment with conventional or high-dose chemotherapy and autologous stem-cell transplantation has been successful in improving progression-free survival." - Anonymous Online Contributor
"The overall 5 year survival rate for diffuse large B-cell lymphoma is 60%. Patients who have an age >60 years or are white have significantly better survival rates than patients who do not meet these criteria. Patients who are black, Hispanic, under age 40 years old or with a poorer performance status has a worse overall survival rate." - Anonymous Online Contributor
"The risk of developing diffuse non-Hodgkin's lymphoma increases significantly with age. After 55 years of age, the risk exceeds that for all other subtypes combined. The most common form of diffuse lymphoma is usual variant Hodgkin's disease." - Anonymous Online Contributor
"LYM-D, although difficult to diagnose, has a long survival time if treated properly utilizing modern chemotherapy regimens. After this disease has been diagnosed, even if its symptoms do not resolve, there is still a chance that the cancer can be cured." - Anonymous Online Contributor
"The addition of alx148 to standard chemotherapy does not appear to improve survival in patients with mantle cell lymphoma. The use of alx148 should be considered when other treatments are being considered." - Anonymous Online Contributor
"There are several risk factors for DLBCL, including: • HIV infection;\n• Immunosuppressive therapy (e.g. peripheral TSLP);\n• Smoking;\n• Exposure to pesticides;\n• Occupational exposures (e.g. exposure to benzene, toluene, styrene, etc." - Anonymous Online Contributor
"The differences in survival between patients with and without radiotherapy suggest that the duration of disease has important prognostic significance, and that early treatment improves long-term survival. We therefore recommend that patients with node-positive stage I and II B-cell lymphoma should be treated within 4 weeks after diagnosis. Patients with stages III and IV disease should be treated before chemotherapy has been given." - Anonymous Online Contributor